vs
CUMBERLAND PHARMACEUTICALS INC（CPIX）与礼来（RNA）财务数据对比。点击上方公司名可切换其他公司
CUMBERLAND PHARMACEUTICALS INC的季度营收约是礼来的1.1倍（$13.7M vs $12.5M），CUMBERLAND PHARMACEUTICALS INC净利率更高（-10.3% vs -1398.3%，领先1388.0%），礼来同比增速更快（434.0% vs 31.1%），CUMBERLAND PHARMACEUTICALS INC自由现金流更多（$3.0K vs $-156.9M），过去两年礼来的营收复合增速更高（138.5% vs 26.9%）
坎伯兰制药是一家专科制药企业，专注于开发、生产和商业化品牌处方药物，核心产品覆盖急症护理、胃肠病、疼痛管理及罕见病治疗领域，主要运营市场为美国，为相关医护人员与患者提供服务。
礼来是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，在18个国家设有办事处，产品销往全球约125个国家。公司由美国内战时期联邦军退伍军人、药剂师伊莱·礼来于1876年创立，品牌名即取自创始人姓名。
CPIX vs RNA — 直观对比
营收规模更大
CPIX
是对方的1.1倍
$12.5M
营收增速更快
RNA
高出403.0%
31.1%
净利率更高
CPIX
高出1388.0%
-1398.3%
自由现金流更多
CPIX
多$156.9M
$-156.9M
两年增速更快
RNA
近两年复合增速
26.9%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.7M | $12.5M |
| 净利润 | $-1.4M | $-174.4M |
| 毛利率 | 83.6% | — |
| 营业利润率 | -10.0% | -1513.5% |
| 净利率 | -10.3% | -1398.3% |
| 营收同比 | 31.1% | 434.0% |
| 净利润同比 | 25.8% | -117.0% |
| 每股收益（稀释后） | $-0.09 | $-1.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPIXRNA
| Q4 25 | $13.7M | — | ||
| Q3 25 | $8.3M | $12.5M | ||
| Q2 25 | $10.8M | $3.8M | ||
| Q1 25 | $11.7M | $1.6M | ||
| Q4 24 | $10.4M | $3.0M | ||
| Q3 24 | $9.1M | $2.3M | ||
| Q2 24 | $9.8M | $2.0M | ||
| Q1 24 | $8.5M | $3.5M |
净利润CPIXRNA
| Q4 25 | $-1.4M | — | ||
| Q3 25 | $-1.9M | $-174.4M | ||
| Q2 25 | $-740.7K | $-157.3M | ||
| Q1 25 | $1.3M | $-115.8M | ||
| Q4 24 | $-1.9M | $-102.3M | ||
| Q3 24 | $-1.5M | $-80.4M | ||
| Q2 24 | $-1.1M | $-70.8M | ||
| Q1 24 | $-1.9M | $-68.9M |
毛利率CPIXRNA
| Q4 25 | 83.6% | — | ||
| Q3 25 | 88.1% | — | ||
| Q2 25 | 81.4% | — | ||
| Q1 25 | 87.8% | — | ||
| Q4 24 | 81.1% | — | ||
| Q3 24 | 85.4% | — | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 81.5% | — |
营业利润率CPIXRNA
| Q4 25 | -10.0% | — | ||
| Q3 25 | -23.7% | -1513.5% | ||
| Q2 25 | -6.9% | -4448.7% | ||
| Q1 25 | 11.0% | -8360.9% | ||
| Q4 24 | -17.7% | -4069.6% | ||
| Q3 24 | -18.6% | -4200.9% | ||
| Q2 24 | -10.4% | -4040.4% | ||
| Q1 24 | -22.0% | -2178.6% |
净利率CPIXRNA
| Q4 25 | -10.3% | — | ||
| Q3 25 | -23.4% | -1398.3% | ||
| Q2 25 | -6.8% | -4089.3% | ||
| Q1 25 | 10.7% | -7360.0% | ||
| Q4 24 | -18.2% | -3439.5% | ||
| Q3 24 | -17.0% | -3441.7% | ||
| Q2 24 | -11.0% | -3461.8% | ||
| Q1 24 | -22.9% | -1943.4% |
每股收益（稀释后）CPIXRNA
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-0.13 | $-1.27 | ||
| Q2 25 | $-0.05 | $-1.21 | ||
| Q1 25 | $0.08 | $-0.90 | ||
| Q4 24 | $-0.13 | $-0.80 | ||
| Q3 24 | $-0.11 | $-0.65 | ||
| Q2 24 | $-0.08 | $-0.65 | ||
| Q1 24 | $-0.14 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.4M | $350.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $24.9M | $1.9B |
| 总资产 | $76.8M | $2.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPIXRNA
| Q4 25 | $11.4M | — | ||
| Q3 25 | $15.2M | $350.2M | ||
| Q2 25 | $16.1M | $243.9M | ||
| Q1 25 | $15.1M | $254.2M | ||
| Q4 24 | $18.0M | $219.9M | ||
| Q3 24 | $17.5M | $370.2M | ||
| Q2 24 | $17.3M | $575.8M | ||
| Q1 24 | $18.5M | $471.4M |
股东权益CPIXRNA
| Q4 25 | $24.9M | — | ||
| Q3 25 | $26.1M | $1.9B | ||
| Q2 25 | $28.0M | $1.2B | ||
| Q1 25 | $28.7M | $1.3B | ||
| Q4 24 | $22.9M | $1.4B | ||
| Q3 24 | $24.8M | $1.5B | ||
| Q2 24 | $26.3M | $1.2B | ||
| Q1 24 | $27.5M | $830.9M |
总资产CPIXRNA
| Q4 25 | $76.8M | — | ||
| Q3 25 | $65.9M | $2.1B | ||
| Q2 25 | $67.9M | $1.4B | ||
| Q1 25 | $69.9M | $1.5B | ||
| Q4 24 | $75.6M | $1.6B | ||
| Q3 24 | $76.7M | $1.6B | ||
| Q2 24 | $78.5M | $1.3B | ||
| Q1 24 | $81.5M | $951.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0K | $-156.2M |
| 自由现金流经营现金流 - 资本支出 | $3.0K | $-156.9M |
| 自由现金流率自由现金流/营收 | 0.0% | -1257.6% |
| 资本支出强度资本支出/营收 | 0.0% | 5.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $4.8M | $-592.3M |
8季度趋势，按日历期对齐
经营现金流CPIXRNA
| Q4 25 | $3.0K | — | ||
| Q3 25 | $187.2K | $-156.2M | ||
| Q2 25 | $843.8K | $-199.7M | ||
| Q1 25 | $3.9M | $-124.8M | ||
| Q4 24 | $1.9M | $-99.9M | ||
| Q3 24 | $475.5K | $-65.6M | ||
| Q2 24 | $-855.7K | $-65.0M | ||
| Q1 24 | $-2.1M | $-70.4M |
自由现金流CPIXRNA
| Q4 25 | $3.0K | — | ||
| Q3 25 | $163.4K | $-156.9M | ||
| Q2 25 | $817.3K | $-203.0M | ||
| Q1 25 | $3.9M | $-128.6M | ||
| Q4 24 | $1.9M | $-103.8M | ||
| Q3 24 | $460.1K | $-67.3M | ||
| Q2 24 | $-862.8K | $-65.5M | ||
| Q1 24 | $-2.2M | $-71.3M |
自由现金流率CPIXRNA
| Q4 25 | 0.0% | — | ||
| Q3 25 | 2.0% | -1257.6% | ||
| Q2 25 | 7.5% | -5277.1% | ||
| Q1 25 | 32.9% | -8174.3% | ||
| Q4 24 | 18.2% | -3491.0% | ||
| Q3 24 | 5.1% | -2881.8% | ||
| Q2 24 | -8.8% | -3204.6% | ||
| Q1 24 | -25.6% | -2012.3% |
资本支出强度CPIXRNA
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.3% | 5.7% | ||
| Q2 25 | 0.2% | 86.9% | ||
| Q1 25 | 0.4% | 238.6% | ||
| Q4 24 | 0.0% | 131.7% | ||
| Q3 24 | 0.2% | 72.9% | ||
| Q2 24 | 0.1% | 26.0% | ||
| Q1 24 | 0.5% | 25.8% |
现金转化率CPIXRNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.10× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
